Converting IR to ER Stimulants: Dosing Strategy
When converting from immediate-release (IR) to extended-release (ER) stimulant formulations, use the total daily IR dose as your starting ER dose, but be prepared to increase the ER dose by 20-50% above the IR equivalent in over half of patients to achieve comparable symptom control. 1
Key Conversion Principles
Starting Dose Equivalency
- Begin with 1:1 conversion: Calculate the total daily IR dose and use this as your initial ER dose 1
- For methylphenidate (MPH): If patient takes 10 mg IR three times daily (30 mg total), start with 30 mg ER formulation
- For amphetamine (AMP/DEX): If patient takes 5 mg IR twice daily (10 mg total), start with 10 mg ER formulation
Critical Caveat: Expect Dose Adjustments
Research demonstrates that simple 1:1 conversion frequently fails. A retrospective analysis found that 55% of patients required higher-than-equivalent ER doses for successful conversion, and 43% needed supplemental IR doses added to their ER regimen 2. This is a common pitfall—don't assume equivalent dosing will work.
Practical Conversion Algorithm
Step 1: Calculate Total Daily IR Dose
- Add all IR doses taken throughout the day
- Example: MPH 10 mg at 8am + 10 mg at noon + 5 mg at 4pm = 25 mg total daily dose
Step 2: Initial ER Conversion
- Start ER formulation at the calculated total daily IR dose
- Administer once daily in the morning with breakfast 1
Step 3: Titration Strategy (Weeks 1-4)
If symptom control is inadequate after 1 week:
- Increase ER dose by 10-20 mg for MPH or 5-10 mg for AMP weekly 1
- Monitor using standardized ADHD rating scales from multiple sources (parents, teachers, self-report for adults) 1
- Continue titration until symptoms resolve or side effects emerge
Step 4: Address Coverage Gaps
When ER formulation provides insufficient afternoon/evening coverage:
- Add small IR dose (5 mg MPH or 2.5 mg AMP) in late afternoon rather than increasing ER dose further 2
- Time this supplemental dose 4-6 hours after morning ER dose
- This approach minimizes sleep disruption while extending coverage 1
Maximum Dosing Parameters
Methylphenidate
- Standard maximum: 60 mg total daily dose (per PDR) 1
- Expert consensus allows up to 72 mg for ER formulations in select cases 3
- Single dose should not exceed 25 mg when using multiple daily doses 1
Amphetamine/Dextroamphetamine
- Standard maximum: 40 mg total daily dose (per PDR) 1
- Some adults may require up to 0.9 mg/kg or 65 mg daily for extended coverage 1
Weight-Based Considerations
- Children <25 kg: Do not exceed 15 mg single dose MPH or 10 mg AMP 1
- Use lower end of dosing ranges and titrate more cautiously in smaller patients
Monitoring Requirements
Initial Conversion Phase (Weeks 1-5)
- Weekly assessment via phone or office visit 1
- Collect ADHD rating scales from all relevant observers
- Document side effects systematically (appetite, sleep, mood, cardiovascular) 1
- Measure blood pressure, pulse, height, and weight at baseline and week 5 1
Maintenance Phase
- Children: Annual vital signs during routine physical 1
- Adults: Quarterly blood pressure and pulse checks 1
Common Pitfalls to Avoid
Assuming 1:1 equivalency will suffice: Most patients need dose adjustment upward 2
Ignoring timing of symptom breakthrough: If symptoms return in late afternoon, add IR booster rather than increasing morning ER dose excessively 1, 2
Failing to obtain multi-source ratings: Rely on validated rating scales from parents, teachers, and patients—not just clinical impression 1
Stopping titration prematurely: Continue weekly increases until optimal response or side effects emerge, not just "some improvement" 1
Overlooking formulation differences: ER products have varying release profiles (biphasic vs. continuous); some patients respond better to specific formulations 4, 5
When Conversion Fails
If adequate symptom control is not achieved at maximum recommended doses:
- Consider switching stimulant class (MPH to AMP or vice versa) rather than exceeding dose limits 1
- Reassess diagnosis and comorbidities
- Implement or intensify behavioral interventions 1
The evidence strongly supports that ER formulations improve compliance and reduce stigma from school dosing, but successful conversion requires active titration and willingness to exceed simple dose equivalency in the majority of patients 2.